Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab

Won Kyung Song, Yoo Hong Min, Yu Ri Kim, Sungchul Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To report on the clinical characteristics and treatment outcomes of cytomegalovirus (CMV) retinitis cases that occurred after allogeneic hematopoietic stem cell transplantation (HSCT) using an alemtuzumab-based (Campath-1H, Genzyme, Cambridge, MA) conditioning regimen. Design: A retrospective noncomparative interventional case series. Participants: Seven eyes of 4 patients in whom CMV retinitis developed after allogeneic HSCT using alemtuzumab. Methods: A retrospective chart review was performed. CMV retinitis was diagnosed by the presence of characteristic ophthalmoscopic findings and confirmed by polymerase chain reaction-based detection of CMV in vitreal biopsy specimens. The affected eyes received intravitreal injections of 2 mg/0.1 mL of ganciclovir twice weekly during induction therapy until the lesions were inactive, followed by weekly injections as maintenance therapy. Maintenance intravitreal therapy continued until the lesions consisted of an atrophic retina with pigment epithelium mottling and attenuated vessels. Main Outcome Measures: Visual acuity, response of retinitis lesions, and postoperative complications. Results: From 1999 to 2007, 294 patients received allogeneic HSCTs at our institution. Among the HSCTs, 65 were unrelated transplants, and of these, 17 were performed using alemtuzumab-based conditioning regimens. Only 4 patients went on to develop CMV retinitis. These 4 patients had several features in common. All patients received transplants from unrelated donors after an alemtuzumab-conditioning regimen for acute leukemia. One patient died before initiation of treatment. Three patients exhibited a bilateral disease, and 3 patients had neutropenia. Patients underwent a mean of 8.3 intravitreal ganciclovir injections in each eye. All 3 treated patients showed a good response. The treatment was well tolerated without serious adverse events during the mean follow-up period of 8.5 months (range, 4.5-16 months). Conclusions: An increased incidence of CMV retinitis was noted in unrelated patients undergoing HSCT using a nonmyeloablative alemtuzumab-based conditioning regimen. Intravitreal ganciclovir therapy seems to be an acceptable therapeutic option in these patients given the nature of their systemic illness, which prohibits the use of typical systemic anti-CMV drugs. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish
Pages (from-to)1766-1770
Number of pages5
JournalOphthalmology
Volume115
Issue number10
DOIs
Publication statusPublished - 2008 Oct 1

Fingerprint

Cytomegalovirus Retinitis
Hematopoietic Stem Cell Transplantation
Ganciclovir
Intravitreal Injections
Cytomegalovirus
Therapeutics
alemtuzumab
Transplants
Retinitis
Unrelated Donors
Disclosure
Neutropenia
Visual Acuity
Retina

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Song, Won Kyung ; Min, Yoo Hong ; Kim, Yu Ri ; Lee, Sungchul. / Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab. In: Ophthalmology. 2008 ; Vol. 115, No. 10. pp. 1766-1770.
@article{28875958f20746a48678730d0fd02da4,
title = "Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab",
abstract = "Objective: To report on the clinical characteristics and treatment outcomes of cytomegalovirus (CMV) retinitis cases that occurred after allogeneic hematopoietic stem cell transplantation (HSCT) using an alemtuzumab-based (Campath-1H, Genzyme, Cambridge, MA) conditioning regimen. Design: A retrospective noncomparative interventional case series. Participants: Seven eyes of 4 patients in whom CMV retinitis developed after allogeneic HSCT using alemtuzumab. Methods: A retrospective chart review was performed. CMV retinitis was diagnosed by the presence of characteristic ophthalmoscopic findings and confirmed by polymerase chain reaction-based detection of CMV in vitreal biopsy specimens. The affected eyes received intravitreal injections of 2 mg/0.1 mL of ganciclovir twice weekly during induction therapy until the lesions were inactive, followed by weekly injections as maintenance therapy. Maintenance intravitreal therapy continued until the lesions consisted of an atrophic retina with pigment epithelium mottling and attenuated vessels. Main Outcome Measures: Visual acuity, response of retinitis lesions, and postoperative complications. Results: From 1999 to 2007, 294 patients received allogeneic HSCTs at our institution. Among the HSCTs, 65 were unrelated transplants, and of these, 17 were performed using alemtuzumab-based conditioning regimens. Only 4 patients went on to develop CMV retinitis. These 4 patients had several features in common. All patients received transplants from unrelated donors after an alemtuzumab-conditioning regimen for acute leukemia. One patient died before initiation of treatment. Three patients exhibited a bilateral disease, and 3 patients had neutropenia. Patients underwent a mean of 8.3 intravitreal ganciclovir injections in each eye. All 3 treated patients showed a good response. The treatment was well tolerated without serious adverse events during the mean follow-up period of 8.5 months (range, 4.5-16 months). Conclusions: An increased incidence of CMV retinitis was noted in unrelated patients undergoing HSCT using a nonmyeloablative alemtuzumab-based conditioning regimen. Intravitreal ganciclovir therapy seems to be an acceptable therapeutic option in these patients given the nature of their systemic illness, which prohibits the use of typical systemic anti-CMV drugs. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.",
author = "Song, {Won Kyung} and Min, {Yoo Hong} and Kim, {Yu Ri} and Sungchul Lee",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.ophtha.2008.04.015",
language = "English",
volume = "115",
pages = "1766--1770",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10",

}

Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab. / Song, Won Kyung; Min, Yoo Hong; Kim, Yu Ri; Lee, Sungchul.

In: Ophthalmology, Vol. 115, No. 10, 01.10.2008, p. 1766-1770.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab

AU - Song, Won Kyung

AU - Min, Yoo Hong

AU - Kim, Yu Ri

AU - Lee, Sungchul

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objective: To report on the clinical characteristics and treatment outcomes of cytomegalovirus (CMV) retinitis cases that occurred after allogeneic hematopoietic stem cell transplantation (HSCT) using an alemtuzumab-based (Campath-1H, Genzyme, Cambridge, MA) conditioning regimen. Design: A retrospective noncomparative interventional case series. Participants: Seven eyes of 4 patients in whom CMV retinitis developed after allogeneic HSCT using alemtuzumab. Methods: A retrospective chart review was performed. CMV retinitis was diagnosed by the presence of characteristic ophthalmoscopic findings and confirmed by polymerase chain reaction-based detection of CMV in vitreal biopsy specimens. The affected eyes received intravitreal injections of 2 mg/0.1 mL of ganciclovir twice weekly during induction therapy until the lesions were inactive, followed by weekly injections as maintenance therapy. Maintenance intravitreal therapy continued until the lesions consisted of an atrophic retina with pigment epithelium mottling and attenuated vessels. Main Outcome Measures: Visual acuity, response of retinitis lesions, and postoperative complications. Results: From 1999 to 2007, 294 patients received allogeneic HSCTs at our institution. Among the HSCTs, 65 were unrelated transplants, and of these, 17 were performed using alemtuzumab-based conditioning regimens. Only 4 patients went on to develop CMV retinitis. These 4 patients had several features in common. All patients received transplants from unrelated donors after an alemtuzumab-conditioning regimen for acute leukemia. One patient died before initiation of treatment. Three patients exhibited a bilateral disease, and 3 patients had neutropenia. Patients underwent a mean of 8.3 intravitreal ganciclovir injections in each eye. All 3 treated patients showed a good response. The treatment was well tolerated without serious adverse events during the mean follow-up period of 8.5 months (range, 4.5-16 months). Conclusions: An increased incidence of CMV retinitis was noted in unrelated patients undergoing HSCT using a nonmyeloablative alemtuzumab-based conditioning regimen. Intravitreal ganciclovir therapy seems to be an acceptable therapeutic option in these patients given the nature of their systemic illness, which prohibits the use of typical systemic anti-CMV drugs. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.

AB - Objective: To report on the clinical characteristics and treatment outcomes of cytomegalovirus (CMV) retinitis cases that occurred after allogeneic hematopoietic stem cell transplantation (HSCT) using an alemtuzumab-based (Campath-1H, Genzyme, Cambridge, MA) conditioning regimen. Design: A retrospective noncomparative interventional case series. Participants: Seven eyes of 4 patients in whom CMV retinitis developed after allogeneic HSCT using alemtuzumab. Methods: A retrospective chart review was performed. CMV retinitis was diagnosed by the presence of characteristic ophthalmoscopic findings and confirmed by polymerase chain reaction-based detection of CMV in vitreal biopsy specimens. The affected eyes received intravitreal injections of 2 mg/0.1 mL of ganciclovir twice weekly during induction therapy until the lesions were inactive, followed by weekly injections as maintenance therapy. Maintenance intravitreal therapy continued until the lesions consisted of an atrophic retina with pigment epithelium mottling and attenuated vessels. Main Outcome Measures: Visual acuity, response of retinitis lesions, and postoperative complications. Results: From 1999 to 2007, 294 patients received allogeneic HSCTs at our institution. Among the HSCTs, 65 were unrelated transplants, and of these, 17 were performed using alemtuzumab-based conditioning regimens. Only 4 patients went on to develop CMV retinitis. These 4 patients had several features in common. All patients received transplants from unrelated donors after an alemtuzumab-conditioning regimen for acute leukemia. One patient died before initiation of treatment. Three patients exhibited a bilateral disease, and 3 patients had neutropenia. Patients underwent a mean of 8.3 intravitreal ganciclovir injections in each eye. All 3 treated patients showed a good response. The treatment was well tolerated without serious adverse events during the mean follow-up period of 8.5 months (range, 4.5-16 months). Conclusions: An increased incidence of CMV retinitis was noted in unrelated patients undergoing HSCT using a nonmyeloablative alemtuzumab-based conditioning regimen. Intravitreal ganciclovir therapy seems to be an acceptable therapeutic option in these patients given the nature of their systemic illness, which prohibits the use of typical systemic anti-CMV drugs. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=52949083167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949083167&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2008.04.015

DO - 10.1016/j.ophtha.2008.04.015

M3 - Article

C2 - 18562004

AN - SCOPUS:52949083167

VL - 115

SP - 1766

EP - 1770

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10

ER -